



## **Inologic Appoints Beatrice Langton-Webster as Vice President, Drug Development**

**SEATTLE, Washington, May 8, 2002** -- Inologic, Inc. today announced the appointment of Bea Langton-Webster, Ph.D., as Vice President, Drug Development. Dr. Langton-Webster will manage the advancement of Inologics' lead compounds through preclinical and early-stage clinical development.

Dr. Langton-Webster has over 18 years experience in the biopharmaceutical industry with particular expertise in preclinical and early-stage clinical program design and management, strategic product planning and establishing strategic collaborative opportunities. Prior to joining Inologic, she served as Vice President, Research and Preclinical Development at Cytran, a Seattle-based biotechnology company. In this role, she was instrumental in helping to define the immunotherapeutic properties of Cytrans' lead drug and its potential clinical utility in combination with chemotherapeutic regimens. Prior to her experience at Cytran, she served as President of her own consulting company, Senior Director, Preclinical Development for Megabios Corporation (now Valentis Corporation) and Head of the Oncology Strategic Research Unit at Triton/Berlex Biosciences (Schering AG). Her scientific efforts and interests have focused on biological therapies and the identification of therapeutic agents that affect cell signaling. She holds a B.A. in Bacteriology from University of California, Los Angeles and a Ph. D. in medical microbiology and immunology from the University of California, Davis. She is also the inventor on a number of pivotal patents related to the erbB-2 (HER-2/neu) antibody.

"Attracting Dr. Langton-Webster to Inologic is an important milestone. She brings to Inologic a strong understanding of the drug discovery and development process and will be instrumental in bringing our lead compounds through preclinical development and into clinical trials," commented Ed Field, President of Inologic.

"I am very pleased and excited to be joining Inologic. Capitalizing on an excellent research team and innovative drug design and discovery, Inologic now has a pipeline of proprietary signaling compounds that have demonstrated efficacy in a number of preclinical disease models. I look forward to establishing and mobilizing a drug development effort to advance these promising lead compounds into human clinical trials and further validate their therapeutic potential," commented Dr. Langton-Webster.

### **About Inologic**

Inologic, Inc. is a biopharmaceutical company focusing on an entirely new class of proprietary compounds based on inomics - the study of a specific class of cell-signaling molecules. Inologic believes its proprietary compounds can alter or manage the signaling pathways that are linked to many serious diseases, including inflammation, cystic fibrosis, cancer, diabetes, central nervous system disorders and diarrhea. Inologic will initially focus its development efforts on the advancement of compounds to treat inflammation and cystic fibrosis.

For more information on Inologic, please contact Ed Field, President at 206.448.9226, [edfield@inologic.com](mailto:edfield@inologic.com).